Status:
NOT_YET_RECRUITING
Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities
Lead Sponsor:
Beijing Hospital
Conditions:
Age-related Macular Degeneration (ARMD)
Eligibility:
All Genders
50+ years
Brief Summary
Age-related macular degeneration (AMD) is one of the main causes of blindness in the elderly population. Intraocular injection of anti-VEGF drugs for neovascular AMD (nAMD) is the main treatment metho...
Eligibility Criteria
Inclusion
- Patients diagnosed with nAMD by ophthalmic examinations including OCT, OCTA, FFA and ICGA;
- Complete clinical data and imaging data of patients were available at baseline, 3 months and 1 year after anti-VEGF treatment.
Exclusion
- Medical records showed other diseases affecting visual function or fundus imaging, such as macular edema, glaucoma, ocular trauma, etc;
- Medical records showed that two or more macular lesions coexist in the affected eye;
- Medical records showed that patients received other treatments within 1 year of anti-VEGF therapy, such as intraocular laser therapy or ocular surgery;
- Medical records showed that there were ocular media opacity, dense macular hemorrhage, or severe macular atrophy, resulting in the inability to accurately measure the required parameters;
- Medical records showed the use of drugs known to cause retinal toxicity, or a history of radiation exposure.
Key Trial Info
Start Date :
October 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
2600 Patients enrolled
Trial Details
Trial ID
NCT06583109
Start Date
October 1 2024
End Date
June 1 2026
Last Update
September 3 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.